Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines.
about
The Antibody Response against HIV-1Challenges in mucosal HIV vaccine development: lessons from non-human primate modelsLive attenuated Rev-independent Nef¯SIV enhances acquisition of heterologous SIVsmE660 in acutely vaccinated rhesus macaquesAAV-Delivered Antibody Mediates Significant Protective Effects against SIVmac239 Challenge in the Absence of Neutralizing ActivityAntigenic properties of the human immunodeficiency virus envelope glycoprotein gp120 on virions bound to target cellsVaccination against heterologous R5 clade C SHIV: prevention of infection and correlates of protectionBiocompatible anionic polymeric microspheres as priming delivery system for effetive HIV/AIDS Tat-based vaccinesStructural Definition of an Antibody-Dependent Cellular Cytotoxicity Response Implicated in Reduced Risk for HIV-1 InfectionDiverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 bindingMeasurements of immune responses for establishing correlates of vaccine protection against HIVSurvivors Remorse: antibody-mediated protection against HIV-1.Identification of dominant antibody-dependent cell-mediated cytotoxicity epitopes on the hemagglutinin antigen of pandemic H1N1 influenza virus.Limited impact of passive non-neutralizing antibody immunization in acute SIV infection on viremia control in rhesus macaques.Induction of Potent and Long-Lived Antibody and Cellular Immune Responses in the Genitorectal Mucosa Could be the Critical Determinant of HIV Vaccine Efficacy.Anti-HIV activity in cervical-vaginal secretions from HIV-positive and -negative women correlate with innate antimicrobial levels and IgG antibodiesConstruction and immunogenicity of replication-competent adenovirus 5 host range mutant recombinants expressing HIV-1 gp160 of SF162 and TV1 strains.Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvantNew paradigms for functional HIV-specific nonneutralizing antibodiesMultiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccinesGenomic analysis reveals pre- and postchallenge differences in a rhesus macaque AIDS vaccine trial: insights into mechanisms of vaccine efficacyInduction of immunity to human immunodeficiency virus type-1 by vaccination.Rapid SIV Env-specific mucosal and serum antibody induction augments cellular immunity in protecting immunized, elite-controller macaques against high dose heterologous SIV challenge.Compromised NK cell-mediated antibody-dependent cellular cytotoxicity in chronic SIV/SHIV infection.B cell responses to HIV-1 infection and vaccination: pathways to preventing infection.Activation of NK cells by ADCC responses during early HIV infection.Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopesVaccine-elicited SIV and HIV envelope-specific IgA and IgG memory B cells in rhesus macaque peripheral blood correlate with functional antibody responses and reduced viremia.Immune escape from HIV-specific antibody-dependent cellular cytotoxicity (ADCC) pressureAntibody-dependent cell-mediated viral inhibition emerges after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys coincident with gp140-binding antibodies and is effective against neutralization-resistant viruses.Early short-term antiretroviral therapy is associated with a reduced prevalence of CD8(+)FoxP3(+) T cells in simian immunodeficiency virus-infected controller rhesus macaques.An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum.Herpes simplex type 2 virus deleted in glycoprotein D protects against vaginal, skin and neural disease.Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection.Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges.Lack of protection following passive transfer of polyclonal highly functional low-dose non-neutralizing antibodiesPotent functional antibody responses elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults.No acquisition: a new ambition for HIV vaccine development?Vaccine induced antibodies to the first variable loop of human immunodeficiency virus type 1 gp120, mediate antibody-dependent virus inhibition in macaques.Replicating adenovirus-simian immunodeficiency virus (SIV) vectors efficiently prime SIV-specific systemic and mucosal immune responses by targeting myeloid dendritic cells and persisting in rectal macrophages, regardless of immunization route.
P2860
Q27000889-3A483D1C-6B2C-402A-B73D-0A863C4B2DEBQ27022152-F83C0AC6-6EA8-47D5-9447-5E08369B0C05Q27305234-D5449D8C-1806-481F-8F0B-4839504C491EQ27318266-18FEF4F1-4586-4E90-B721-CE1CFC67CEDDQ27320687-B034FA82-84E8-43DF-9853-FD1B8364FC7AQ27332360-3FFBC405-3443-4028-AD61-EDBA0A1EE97FQ27333734-76781213-3C96-43CA-A79D-3F33438A520BQ27640572-986476B9-40D7-46D2-AB8D-5C125262DF1EQ27675486-0076AF57-B95F-4E25-9885-D14E8C36DE89Q28728189-897C64F8-E2E6-427A-AD55-B6AEF68A5D31Q30238730-AC5A0000-9647-48FC-838E-614C04DA55CFQ30428189-61A7B82A-2761-48E6-A8EE-0CECAD82A646Q31138949-1A8B53B2-8CA5-4FE1-B05C-1A4799C8959DQ33611645-73F83A43-186A-429C-8DB7-ED7DDEE288E1Q33627673-1632949F-765F-4488-BB31-6D5ACCECF018Q33872445-14A9564A-C01C-4FB5-9BC0-C894BF0B7CBFQ33877513-23C96E64-B1B4-4380-8E19-06517C974E60Q33900595-5F652D8A-8116-4FE6-B6B1-C3031530D765Q33966586-E636294E-B173-46C2-AEEC-CFE42D8AA7BAQ34057711-AC164572-E2A7-440F-B894-63C2ED29CA7AQ34485178-65A7DD3B-B32D-434D-A8E4-DD1654D02BDCQ34540645-61C605F8-F650-40AF-9118-62F32061FD00Q34574409-B10B3031-1A8B-4985-B7C5-64D127FCE7FBQ34592776-AB4DAF74-9EB6-4A6F-8A9A-A0987FBD3738Q34645502-2879AEC6-EA71-4BE4-92A2-4DDE09778154Q34756684-70B446DD-484C-404F-BF4E-C1B343678DB7Q34791232-183B700E-FAC3-4017-9F84-767205F957E5Q34810713-304FE67B-AA94-4E87-99A4-3D56BBA35CE4Q34937296-CDBCBE99-7023-45A6-94BA-3D8045019A7FQ34982646-43E047A9-EACA-4A47-AF0C-80923FE3D53BQ35069126-F3429CBF-60E8-4C0B-A134-B41975DEBA32Q35077677-AF846F5A-3AD7-4959-AE32-46E0B12D0340Q35156674-89068D0F-95B0-4746-A63A-AAC3B0A08134Q35156935-88F84114-C62F-4717-8BC1-29BD2B68C8E3Q35160124-DCB0C986-F1D1-4FE6-8486-B410DE168674Q35167400-0F39E19E-EAEF-4085-9AE4-522526741D46Q35415717-91882B95-4CF8-4B5A-B25E-65299706E582Q35534563-BA5ACDCE-251A-4CA6-B117-FE63782C87FFQ35636394-8A91A4A6-213E-4D52-84DD-539899290E60Q35940685-A95D5C27-EEF7-4BE9-95A8-ECF0E85BE44E
P2860
Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Contribution of nonneutralizin ...... ared with multigenic vaccines.
@en
Contribution of nonneutralizin ...... ared with multigenic vaccines.
@nl
type
label
Contribution of nonneutralizin ...... ared with multigenic vaccines.
@en
Contribution of nonneutralizin ...... ared with multigenic vaccines.
@nl
prefLabel
Contribution of nonneutralizin ...... ared with multigenic vaccines.
@en
Contribution of nonneutralizin ...... ared with multigenic vaccines.
@nl
P2093
P2860
P356
P1476
Contribution of nonneutralizin ...... pared with multigenic vaccines
@en
P2093
Aurelio Cafaro
David Venzon
Kay Larsen
L Ebonita Summers
LaRene Kuller
Marjorie Robert-Guroff
Ruth H Florese
Thorsten Demberg
P2860
P304
P356
10.4049/JIMMUNOL.0803115
P407
P577
2009-03-01T00:00:00Z